Thursday, June 23rd, 2016 adds ‘Refractory Acute Myeloid Leukemia Pipeline Review H1 2016’ Market Research to its database, providing in-depth, high quality, transparent and market-driven, expert’s analysis.

In-detail Table of Contents of Refractory Acute Myeloid Leukemia Pipeline Market

Companies involved in this research 4SC AG, AbbVie Inc., Actinium Pharmaceuticals, Inc., Aeglea BioTherapeutics, Inc., Agios Pharmaceuticals, Inc., Amgen Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Astellas Pharma Inc., AVEO Pharmaceuticals, Inc., Bellicum Pharmaceuticals, Inc., BioLineRx, Ltd., BioSight Ltd., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Celgene Corporation, Cornerstone Pharmaceuticals, Inc., CTI BioPharma Corp., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., EpiZyme, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., FORMA Therapeutics, Inc., Fujifilm Corporation, GlaxoSmithKline Plc, GlycoMimetics, Inc., Igenica Biotherapeutics, Inc., Incyte Corporation, Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, JW Pharmaceutical Corporation, Karyopharm Therapeutics, Inc., Kyowa Hakko Kirin Co., Ltd., Les Laboratoires Servier SAS, MacroGenics, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., NantKwest, Inc., Novartis AG, Oxford BioTherapeutics Ltd, Pfizer Inc., Pharma Mar, S.A., Plexxikon Inc., Polaris Pharmaceuticals, Inc., Seattle Genetics, Inc., Sigma-Tau S.p.A., Sunesis Pharmaceuticals, Inc., TaiGen Biotechnology Co., Ltd., Teva Pharmaceutical Industries Ltd., Threshold Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc., Tragara Pharmaceuticals, Inc., and Verastem, Inc.

Get discount on this research at .

Scope for this research:

  • The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
  • The report reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Refractory Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects
  • The report assesses Refractory Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia

The report provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects.

Complete research report at .

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

File Library

Contact Profile

RnR Market Research

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

Ritesh Tiwari
P: + 1 888 391 5441


Refractory Acute Myeloid Leukemia Pipeline, Refractory Acute Myeloid Leukemia Pipeline market, Refractory Acute Myeloid Leukemia Pipeline market research, Refractory Acute Myeloid Leukemia Pipeline market outlook, Refractory Acute Myeloid Leukemia Pipelin




More Formats

View QR Code